Diabetes

Metabolic·MeSH: Diabetes Mellitus

Prevalence

10700.0 / 100K

Incidence

600.0 / 100K/yr

264 drugs in development·84 companies·30 clinical trials

Drug Pipeline by Phase

Approved(38)
Phase 3(53)
DrugCompany
AbataceptCidara Therapeutics, Inc. (CDTX)
afrezzaMANNKIND CORP (MNKD)
afrezza inhalant productGH Research PLC (GHRS)
AZD6793ASTRAZENECA PLC (AZN)
biological/vaccineVERTEX PHARMACEUTICALS INC / MA (VRTX)
BYDUREONENANTA PHARMACEUTICALS INC (ENTA)
cadisegliatinvTv Therapeutics Inc. (VTVT)
cadisegliatin 800 mg bidvTv Therapeutics Inc. (VTVT)
cadisegliatin 800 mg qdvTv Therapeutics Inc. (VTVT)
cagrisemaNovo Nordisk A/S (NVO)
DulaglutideENANTA PHARMACEUTICALS INC (ENTA)
DulaglutideELI LILLY & Co (LLY)
EmpagliflozinELI LILLY & Co (LLY)
faster-acting insulin aspartNovo Nordisk A/S (NVO)
HDM1005 1Crinetics Pharmaceuticals, Inc. (CRNX)
HDM1005 1ENANTA PHARMACEUTICALS INC (ENTA)
HDM1005 2ENANTA PHARMACEUTICALS INC (ENTA)
HDM1005 2Crinetics Pharmaceuticals, Inc. (CRNX)
horse anti-thymocyte globulinStructure Therapeutics Inc. (GPCR)
IBI362Crinetics Pharmaceuticals, Inc. (CRNX)
icosemaNovo Nordisk A/S (NVO)
idegaspSanofi (SNY)
idegliraNovo Nordisk A/S (NVO)
insulin degludecNovo Nordisk A/S (NVO)
insulin degludecSUNSHINE BIOPHARMA INC. (SBFM)
insulin glargineELI LILLY & Co (LLY)
insulin glargineNovo Nordisk A/S (NVO)
insulin glargine/lixisenatideSanofi (SNY)
insulin icodecNovo Nordisk A/S (NVO)
insuline glargine u100Novo Nordisk A/S (NVO)
Intensified medical follow-up and glucose-lowering drugsTravere Therapeutics, Inc. (TVTX)
KAI-9531ENANTA PHARMACEUTICALS INC (ENTA)
MazdutideENANTA PHARMACEUTICALS INC (ENTA)
MET097PFIZER INC (PFE)
MK-2828Merck & Co., Inc. (MRK)
nnc0487-0111Novo Nordisk A/S (NVO)
oral semaglutideEMISPHERE TECHNOLOGIES INC (EMIS)
oral Semaglutide/RybelsusENANTA PHARMACEUTICALS INC (ENTA)
ormd-0801ORAMED PHARMACEUTICALS INC. (ORMP)
prochymalMesoblast Limited (MESO)
prochymalMesoblast Limited (MESO)
rabbit anti-thymocyte globulinStructure Therapeutics Inc. (GPCR)
rapid-acting insulin analogMANNKIND CORP (MNKD)
RetatrutideELI LILLY & Co (LLY)
SemaglutideELI LILLY & Co (LLY)
SemaglutideENANTA PHARMACEUTICALS INC (ENTA)
semaglutide bNovo Nordisk A/S (NVO)
semaglutide jNovo Nordisk A/S (NVO)
sglt2 inhibitorSanofi (SNY)
teplizumabSanofi (SNY)
TeplizumabSanofi (SNY)
vx-880VERTEX PHARMACEUTICALS INC / MA (VRTX)
zynquistaLEXICON PHARMACEUTICALS, INC. (LXRX)
Phase 2(43)
DrugCompany
ALN-4324ALNYLAM PHARMACEUTICALS, INC. (ALNY)
anakinraENANTA PHARMACEUTICALS INC (ENTA)
anakinraCidara Therapeutics, Inc. (CDTX)
Anti-Thymocyte GlobulinStructure Therapeutics Inc. (GPCR)
Antithymocyte GlobulinENANTA PHARMACEUTICALS INC (ENTA)
Antithymocyte GlobulinStructure Therapeutics Inc. (GPCR)
asc30CHINA PHARMA HOLDINGS, INC. (CPHI)
basal insulinMANNKIND CORP (MNKD)
bmf-219Biomea Fusion, Inc. (BMEA)
brivekimigSanofi (SNY)
bti-320NANOMIX CORP (BTHI)
bti-410NANOMIX CORP (BTHI)
celz-201CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ)
da-1241MetaVia Inc. (MTVA)
DapansutrileValneva SE (VALN)
DegludecELI LILLY & Co (LLY)
eflornithinePANBELA THERAPEUTICS, INC. (SNBP)
empagliflozinCidara Therapeutics, Inc. (CDTX)
GKT137831Calliditas Therapeutics AB (CALT)
GSBR-1290Structure Therapeutics Inc. (GPCR)
high dose sab-142SAB BIOTHERAPEUTICS, INC. (SABS)
icovamenibBiomea Fusion, Inc. (BMEA)
imb-1018972MADRIGAL PHARMACEUTICALS, INC. (MDGL)
insulinSanofi (SNY)
kds2010SCILEX HOLDING CO (SCLX)
low dose sab-142SAB BIOTHERAPEUTICS, INC. (SABS)
LY3457263ELI LILLY & Co (LLY)
LY3938577ELI LILLY & Co (LLY)
lymphocyte immune globulinStructure Therapeutics Inc. (GPCR)
MLR-1023Adhera Therapeutics, Inc. (ATRX)
mn-001MEDICINOVA INC (MNOV)
mots-cIO Biotech, Inc. (IOBT)
nnc0194-0499Novo Nordisk A/S (NVO)
nnc0480-0389Novo Nordisk A/S (NVO)
nnc0487-0111 subcutanousNovo Nordisk A/S (NVO)
nnc0662-0419Novo Nordisk A/S (NVO)
renal autologous cell therapyPROKIDNEY CORP. (PROK)
sab-142SAB BIOTHERAPEUTICS, INC. (SABS)
technosphere insulinMANNKIND CORP (MNKD)
TeplizumabStructure Therapeutics Inc. (GPCR)
trizepatideNovo Nordisk A/S (NVO)
vanoglipelMetaVia Inc. (MTVA)
VK0612Viking Therapeutics, Inc. (VKTX)
Phase 1(44)
DrugCompany
AdalimumabStructure Therapeutics Inc. (GPCR)
AGTX-2004 (DBPR211)Agentix Corp. (AGTX)
amg 127AMGEN INC (AMGN)
Arginine hydrochlorideCidara Therapeutics, Inc. (CDTX)
arm 1 - dehydratech-cbd aloneLexaria Bioscience Corp. (LEXX)
arm 2 - dehydratech-semaglutide aloneLexaria Bioscience Corp. (LEXX)
arm 4 - rybelsus medication aloneLexaria Bioscience Corp. (LEXX)
arm 5- tirzepatideLexaria Bioscience Corp. (LEXX)
BP1001-ABIO-PATH HOLDINGS, INC. (BPTH)
cagrilintideNovo Nordisk A/S (NVO)
CELZ-201 CREATE-1CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ)
dasiglucagonNovo Nordisk A/S (NVO)
degludec ivELI LILLY & Co (LLY)
degludec scELI LILLY & Co (LLY)
dehydratech-cbdLexaria Bioscience Corp. (LEXX)
dehydratech-semaglutideLexaria Bioscience Corp. (LEXX)
dehydratech-tirzepatideLexaria Bioscience Corp. (LEXX)
faster aspartNovo Nordisk A/S (NVO)
insulin aspartNovo Nordisk A/S (NVO)
insulin detemirNovo Nordisk A/S (NVO)
insulin lispro sar342434Sanofi (SNY)
levonorgestrel + ethinylestradiolNovo Nordisk A/S (NVO)
lispro scELI LILLY & Co (LLY)
LY3209590ELI LILLY & Co (LLY)
ly3502970ELI LILLY & Co (LLY)
LY3549492ELI LILLY & Co (LLY)
ly4057996 ivELI LILLY & Co (LLY)
ly4057996 scELI LILLY & Co (LLY)
nnc0363-1063Novo Nordisk A/S (NVO)
nnc0471-0119 hNovo Nordisk A/S (NVO)
nnc0497-0040Novo Nordisk A/S (NVO)
nnc0519-0130Novo Nordisk A/S (NVO)
novo rapidNovo Nordisk A/S (NVO)
OrforglipronELI LILLY & Co (LLY)
paracetamolNovo Nordisk A/S (NVO)
PATAS TrifluoroacetateValneva SE (VALN)
pre-study basal insulin scELI LILLY & Co (LLY)
pyroglutamate rongliflozinSUNSHINE BIOPHARMA INC. (SBFM)
RO7204239Crinetics Pharmaceuticals, Inc. (CRNX)
semaglutide lNovo Nordisk A/S (NVO)
semaglutide mNovo Nordisk A/S (NVO)
semaglutide nNovo Nordisk A/S (NVO)
up421Sana Biotechnology, Inc. (SANA)
verapamil extended-release capsuleStructure Therapeutics Inc. (GPCR)
Preclinical(31)
Phase 4(27)

Compare drugs

Frequently asked questions

How many drugs are in development for Diabetes?

BioSniper tracks 264 drugs in development for Diabetes across 84 companies.

How many clinical trials target Diabetes?

There are 30 clinical trials targeting Diabetes tracked by BioSniper.

What is the prevalence of Diabetes?

The estimated prevalence of Diabetes is approximately 10700.0 per 100,000 population.

Deep-dive into Diabetes

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis